Under the agreement, Cologuard promotional efforts will be expanded efforts through the use of Ironwood’s clinical sales specialists. Ironwood will be compensated from the net sales generated from the physicians on whom they call. The non-exclusive co-promotion agreement covers an initial one-year term with the opportunity for extension.
Cologuard is the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer.
More articles on GI/endoscopy:
Gastroenterology technology company to know: Exalenz Biosciences
26 gastroenterologists making headlines – March 10, 2015
Vegetarian diet associated with reduced CRC risk
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.